10 Best Immunology Stocks To Buy Now

7. Sanofi (NASDAQ:SNY)

Number of Hedge Fund Holders: 33

Sanofi (NASDAQ:SNY) stands seventh among the best immunology stocks to buy now. It is a global healthcare company specializing in innovative medicines and vaccines across immunology, oncology, rare diseases, neurology, and diabetes. It generates revenue by selling prescription drugs, vaccines, and consumer healthcare products to healthcare providers, pharmacies, and governments in over 170 countries.

Sanofi (NASDAQ:SNY) is establishing itself as a leader in immunology research through its “immunoscience” approach, which focuses on understanding immune pathways beyond specific diseases. This strategy allows the company to apply deep biological insights across various therapeutic areas and develop versatile treatments that address multiple conditions.

Sanofi (NASDAQ:SNY)’s immunology research spans gastroenterology, respiratory diseases, dermatology, and immunologic disorders, with additional exploration in neurology, oncology, hematology, rare diseases, and vaccines. As of 2025, its pipeline includes multiple Phase 3 clinical trials and promising oral anti-inflammatory treatments like SAR441566 for psoriasis and rheumatoid arthritis. The company is also advancing 12 potential blockbuster assets, such as Amlitelimab and Frexalimab, each with projected peak sales exceeding €5 billion.

For FY 2024, Sanofi (NASDAQ:SNY) announced total sales of €41.1 billion, an 11.3% increase at constant currency rates (CER). Dupixent made about €13 billion in its first full year, while Beyfortus, a novel RSV vaccination for babies, became a bestseller with €1.7 billion. SNY’s EPS grew 4.1% at CER to €7.12, above the estimate, despite a 1.8% decline in reported terms. The company also proposed a €3.92 dividend for 2024, marking the 30th consecutive year of growth.